An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 04 May 2017
At a glance
- Drugs Rovalpituzumab tesirine (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 28 Apr 2017 Planned End Date changed from 1 Dec 2020 to 25 Mar 2020.
- 28 Apr 2017 Planned initiation date changed from 31 Mar 2017 to 30 Apr 2017.
- 24 Mar 2017 New trial record